首页> 外文期刊>Medical science monitor : >Assessment of iron metabolism in children with chronic hepatitis B - prognostic factor in interferon alpha therapy.
【24h】

Assessment of iron metabolism in children with chronic hepatitis B - prognostic factor in interferon alpha therapy.

机译:慢性乙型肝炎患儿铁代谢的评估-干扰素α治疗的预后因素。

获取原文
获取外文期刊封面目录资料

摘要

BACKGROUND: The aim of the study was to assess iron metabolism in childrenwith chronic hepatitis B and to establish whether it had any influence on the results of interferon alphatherapy. MATERIAL/METHODS: The study was carried out in a group of 38 children aged from 2 to 16 yearswith chronic hepatitis B diagnosed according to serological, biochemical and histopathological criteria.All the patients were treated according to the commonly adopted schedule: interferon alpha administeredsubcutaneously three times a week at 3 MIU doses for 20 weeks. During the therapy and one-year follow-upafter its completion, biochemical liver function parameters, serological HBV markers, and iron and ferritinlevels were monitored. RESULTS: The therapy resulted in obtaining seroconversion in the HBe system in9 patients (23.68%). Liver bioptates in that group of patients demonstrated more advanced changes dueto inflammatory activity and fibrosis processes, significantly higher values of alanine aminotransferase,lower serum levels of iron and ferritin with more pronounced difference in ferritin levels, althoughthe differences reached no statistical significance. CONCLUSIONS: No disturbances of iron metabolismwere observed in children with chronic hepatitis B. In the group of patients with detectable seroconversionin the Hbe system resulting from interferon alpha therapy, lower serum levels of iron and ferritin wereobserved. Routine determinations of serum iron and ferritin levels as a prognostic factor for positiveresponse to interferon alpha seem to be of little use, especially in children, in whom no iron accumulationin liver tissue is observed in histopathological assessment of liver bioptates
机译:背景:这项研究的目的是评估慢性乙型肝炎患儿的铁代谢,并确定其是否对干扰素α疗法的结果有影响。材料/方法:本研究针对38名2至16岁的慢性乙型肝炎儿童进行了研究,这些儿童根据血清学,生化和组织病理学标准被诊断出。每周3次MIU剂量每周20次。在治疗期间和完成后的一年随访中,监测生化肝功能参数,血清HBV标记以及铁和铁蛋白水平。结果:该疗法导致9例患者的HBe系统发生血清转化(23.68%)。该组患者的肝活检显示由于炎症活动和纤维化过程而出现更高级的变化,丙氨酸氨基转移酶的值明显更高,铁和铁蛋白的血清水平较低,铁蛋白水平的差异更为明显,尽管差异无统计学意义。结论:慢性乙型肝炎患儿未发现铁代谢紊乱。在干扰素α治疗导致Hbe系统血清学转变可检测的患者中,血清铁和铁蛋白水平降低。常规测定血清铁和铁蛋白水平作为干扰素α阳性反应的预后因素似乎没有多大用处,特别是在儿童中,他们在肝活检组织病理学评估中未观察到肝组织中铁的积累

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号